Everolimus is an orally active mTOR inhibitor, and VEGF is a potent proangiogenic protein that plays an important role in tumor angiogenesis [10] and acts by binding to the VEGFR on endothelial cells [46]. This evidence concerns the gene VEGFA and neoplasm.